Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track CELZ with free AI briefings, catalyst countdowns, and dilution alerts.

CELZ · CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$8.7M Cash on Hand

18.7mo Cash Runway

Follow CELZ by email Get an email when CELZ pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CELZ, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Jan 2027 · Phase 1/2 · Active Trial · Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the
Registry primary completion date, not a results date
Jan 2027 · Phase 1/2 · Recruiting · Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes
Registry primary completion date, not a results date
May 2029 · N/A · Upcoming Trial · Project PHOENIX: Molecular Signatures of Burn Pit Exposure
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Remimazolam	Anesthesia, Intravenous	Phase 3 · NCT03661489	Completed
C Peptide	Diabetes Mellitus, Type 1	Phase 2 · NCT00278980	Completed
CELZ-201 Administration	Type 1 Diabetes	Phase 1/2 · NCT05626712	Recruiting
CELZ-201-DDT	Chronic Low-back Pain	Phase 1/2 · NCT06053242	Active not recruiting

Also used in these trials (approved or third-party drugs, not CELZ's own candidates): Propofol.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CELZ holds $8.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.4M/quarter from operations, an estimated runway of 18.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 28 · Moderate

Cash runway 19 months +8
Shelf registration (S-3, Oct 2024) +10
Share count +156% in a year +20
Raised after last reported balance sheet (Sep 2026) -10

Recent financing filings on SEC EDGAR:

Sep 25, 2026 · Private placement (8-K Item 3.02) · 8-K
Jul 2, 2026 · Private placement (8-K Item 3.02) · 8-K
Jun 25, 2026 · Registered direct / best-efforts offering · S-1
Oct 31, 2025 · Private placement (8-K Item 3.02) · 8-K
Mar 7, 2025 · Private placement (8-K Item 3.02) · 8-K
Oct 23, 2024 · Registered direct / best-efforts offering · 424B5

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CELZ files for a raise →

Get the full CELZ picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CELZ and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z